Eli Lilly and Company

Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Hoechst Marion Roussel

Other

Aventis Pharmaceuticals Inc.

Aventis Pharma Limited

Douglas Wade Beight

Jason Scott Sawyer

Gary A Flynn

Michael Robert Wiley

Robert T Shuman

John Joseph Masters

Ying Kwong Yee

Gerald Floyd Smith

Steven E Hall

James Howard Wikel

David Kent Herron

Valentine Joseph Klimkowski

David Mendel

Jennifer Marie Tinsley

Anne Louise Tebbe

Trelia Joyce Craft

Leonard Crayton Weir

Jeffry Bernard Franciskovich

Guy Milot

Theodore Goodson, Jr

Jeffrey Alan Kyle

Alan M Warshawsky

John Michael Morin, Jr

Sajan Joseph

Shujaath Mehdi

Daniel Jon Sall

John F French

Ho-Shen Lin

Michael Enrico Richett

Michael Dean Kinnick

Edward C R Smith

John H Kehne

Timothy Paul Burkholder

Marta Maria Pi&ntilde;eiro-N&uacute;&ntilde;ez

William Thomas McMillen

Jonathan Michael Yingling

Philippe Bey

Edward D Daugs

Eugene L Giroux

Michael J Genin

Carl Penman Denny

Nicholas J Bach

Jolie Anne Bastian

Richard Waltz Harper

Robert D Dillard

Michael LeRoy Phillips

Benjamin Alan Anderson

Susan Elizabeth Draheim

Tulio Suarez

Alexander Glenn Godfrey

Edward David Mihelich

Robert Theodore Vasileff

Michael Lyle Denney

Nancy Kay Harn

Hong-Yu Li

Gary A Hite

Richard Walter Schevitz

John Mcneill McGill, Iii

Marta Maria Pi&ntilde;eiro-Nu&ntilde;ez

Richard James Loncharich

Theodore Goodson, Junior

Todd Vincent Decollo

Thomas D Bannister

David Andrew Coates

Joseph P Burkhart

Meena V Patel

Sushant Malhotra

Rosanne Bonjouklian

Jeremy Schulenburg York

Shawn Christopher Miller

Joshua Ryan Clayton

Chi-Hsin Richard King

Michael John Janusz

Thomas Albert Engler

Gaiying Zhao

Ramalinga M Dharanipragada

Yan Wang

Junkai Liao

Brandon Lee Parkhurst

Kenneth James Henry, Jr

Marta Maria Pineiro-Nunez

Craig Daniel Wolfangel

Joseph T Tsay

Clive Gideon Diefenbacher

Huaxing Pei

Charles Raymond Heap

Mark Edward Rempala

Theodore Goodson Jr

Jeffrey Bernard Franciskovich

Sreenivasa Reedy Mundla

MariJean Eggen

John Andrew Buben

Deidre Michelle Johns

Saravanan Parthasarathy

Marta Maria Pinelro-Núnez

John David Jandzinski

Jian Shen

Guy Milet

William T Mcmillen

The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I. 

AKT inhibitors

A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound. 

Quinolinyl-pyrrolopyrazoles

The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds. 

Compounds as pharmaceutical agents

Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

Pyrazolopyridine derivatives as pharmaceutical agents

A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound.

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Aromatic amides

Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S

Pyrrole derivatives as pharmaceutical agents

A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

[object Object]

A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

sPLA2 inhibitors

The present invention relates to certain novel 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase. Pharmaceutical compositions containing said compounds as well as methods of treating various disease states responding to inhibition of matrix metalloproteinase are also claimed herein.

3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Antithrombotic agents

A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

Spla2 inhibitors

A novel class of tetracyclic compounds represented by the formula Iwherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

The invention relates to novel heterocycle substituted diphenyl leukotriene B (LTB ) antagonists, to compositions containing such compounds, and to methods of using such compounds for treatment of inflammatory diseases.

Heterocycle substituted diphenyl leukotriene antagonists

Growing community of inventors

Frankfort, IN, United States of America

Douglas Wade Beight